Digital-first creative agency Code and Theory has established Code and Theory Health – a new business unit dedicated to servicing brands and organizations within the healthcare industry – and added Scout Health, a 100-person agency focused on rare diseases, orphan drugs and specialty pharmaceuticals.
When patients with a rare disease fail to receive a proper diagnosis, treatment plan, and therapy, they can suffer for years. Failed treatments for these prolonged conditions strain patients, caregivers, and the health ecosystem. In addition to the significant physical and emotional struggles these patients endure, delayed diagnoses for rare diseases can also result in many years of lost revenue for manufacturers.
The IQVIA report finds that in 2018, 27% of drugs launched were for cancer or its symptoms, and 20% were for infectious diseases.
SCOUT, a leading healthcare marketing agency focused on orphan drugs and specialty pharmaceuticals, formed a joint venture with Rare Expertise, a company with proprietary data-driven tools for identifying and activating people with rare disorders.
The U.S. FDA approved Genentech’s Actemra (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome in patients 2 years of age and older.
UDG Healthcare plc announced the acquisition of Cambridge BioMarketing LLC, a U.S.-based healthcare communications business, for a total consideration of up to $35 million.
For the eighth year, Med Ad News has chosen three Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
PHOENIX, AZ–(Marketwired – Aug 4, 2015) – Insys Therapeutics, Inc. (NASDAQ: INSY) (“Insys” or “the Company”) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug […]
LAVAL, QUEBEC–(Marketwired – Aug. 4, 2015) – ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), (“ProMetic” or the “Corporation”) announced today that an orphan drug designation status has been granted for its human […]
NORWOOD, MA–(Marketwired – Jun 12, 2015) – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and […]
